The Use of Oxazolidinone Products in the Treatment of Urinary Infections

Authors

  • D.D. Ivanov Department of Nephrology and Renal Replacement Therapy of the National Medical Academy of Postgraduate Education named after P.L. Shupik, Kyiv Clinical Hospital № 18, Kyiv, Ukraine http://orcid.org/0000-0003-2609-0051
  • Ya.O. Dombrovskyi Department of Nephrology and Renal Replacement Therapy of the National Medical Academy of Postgraduate Education named after P.L. Shupik, Kyiv Clinical Hospital № 18, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2307-1257.0.4.14.2015.74896

Keywords:

urinary infections, oxazolidinones, linezolid, Staphylococcus aureus, Enterococcus

Abstract

The clinical efficacy of oxazolidinones with a focus on linezolid application in urinary infections is presented. High activity of the drug in methicillin-resistant Staphylococcus aureus, Enterococcus faecium and Enterococcus faecalis resistant to vancomycin is discussed. Most common situations for effective use of linezolid are defined: septic conditions and the long carriage of the mentioned pathogens.

Downloads

Download data is not yet available.

References

Grabe M., Bjerklund-Johansen T.E. et al. Guidelines on Urologiсal Infections. — European Association of Urology, 2013.

Stamm W.E. Scientific and clinical challenges in the management of urinary tract infections // Am. J. Med. — 113 (1A). — 1S-4S.

Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs // Am. J. Med. — 2002. — 113 (Suppl. 1A). — Р. 5s-13s.

Schappert S.M. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1997 // Vital Health Stat. 13. — 1999. — 143. — 1-39.

Foxman B., Barlow R., d’Arcy H. et al. Urinary tract infection: estimated incidence and associated costs // Ann. Epidemiol. — 2000. — 10. — 509-515.

Kunin C.M. Urinary tract infections in females // Clin. Infect. Dis. — 1994. — 18. — 1-12.

Winberg J., Bergstron T., Jacobsson B. Morbidity, age and sex distribution: recurrences and renal scarring in symptomatic urinary tract infection in childhood // Kidney Int. Suppl. — 1975. — 3 (suppl.). — S101–S106.

Carlet J. et al. Society’s failure to protect a precious resource: antibiotics // Lancet. — 2011. — 378(9788). — Р. 369-71.

Gyssens I.C. Antibiotic policy // Int. J. Antimicrob Agents. — 2011. — 38 Suppl. — Р. 11-20.

Karlowsky J.A., Kelly L.J., Thornsberry C., Jones M.E., Sahm D.F. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States // Antimicrob. Agents Chemother. — 2002 Aug. — 46(8). —2540-5.

Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe // The ECO.SENS study. — 2003 Oct. — 22 (Suppl. 2). — 49-52.

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI Approved Standard M100-S16. — Wayne, PA: The Institute, 2006.

Lodise T.P., Graves J., Evans A. et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureusbacteremia treated with vancomycin // Antimicrob. Agents Chemother. — 2008. — 52(9). — 3315-3320.

Morrison M.A., Hageman J.C., Klevens R.M. Case definition for community-associated methicillin-resistant Staphylococcus aureus // J. Hosp. Infect. — 2006. — 62(2). — 241.

MacGowan A.P. Pharmacokinetic and pharmacodynamics profile of linezolid in healthy volunteers and patients with Gram-positive infections // J. Antimicrob. Chemother. — 2003. — 51 (Suppl. 2). — 17-25.

Jodal U. The natural history of bacteriuria in childhood // Infect Dis Clin North Am. — 1987. — 1(4). — Р. 713-29

Miletín J., Melichar J., Janota J., Mikoláqová B., Jedlicková A., Kucera J., Cunát V., Stranák Z. The first experience with linezolide in treatment of nosocomial septic condition in premature neonates // Ceska Gynekol. — 2004 Dec. — 69 (Suppl. 1). — 102-4.

Leach K.L., Brickner S.J., Noe M.C., Miller P.F. Linezolid, the first oxazolidinone antibacterial agent // Ann. NY Acad. Sci. — 2011. — 1222. — 49-54.

Wiskirchen D.E., Shepard A., Kuti J.L., Nicolau D.P. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis // Antimicrob. Agents Chemother. — 2011. — 55(7). — 3220-3225.

Bernardo K., Pakulat N., Fleer S. et al. Subinhibitory concentrations of linezolid reduceStaphylococcus aureus virulence factor expression // Antimicrob. Agents Chemother. — 2004. — 48(2). — 546-555.

Kafil H.S., Asgharzadeh M. Vancomycin-resistant enteroccus faecium and Enterococcus faecalis isolated from education hospital of Iran // Maedica (Buchar). —2014 Dec. — 9(4). — 323-7.

Eden G., Burkhardt O., Clajus C., Kielstein J.T. Daptomycin for a complicated urinary tract infection with vancomycin-resistant Enterococcus faecium in a renal transplant recipient // Clin. Kidney J. — 2012 Aug. — 5(4). — 350-1.

Swaminathan S., Alangaden G.J. Treatment of resistant enterococcal urinary tract infections // Curr. Infect. Dis. Rep. — 2010 Nov. — 12(6). — 455-64.

Wagenlehner F.M., Naber K.G. New drugs for Gram-positive uropathogens // Int. J. Antimicrob. Agents. — 2004 Sep. — 24 (Suppl. 1). — S39-43.

Downloads

Published

2022-01-19

How to Cite

Ivanov, D., & Dombrovskyi, Y. (2022). The Use of Oxazolidinone Products in the Treatment of Urinary Infections. KIDNEYS, (4.14), 50–54. https://doi.org/10.22141/2307-1257.0.4.14.2015.74896

Issue

No. 4.14 (2015)

Section

Reviews

License

Copyright (c) 2015 D.D. Ivanov, Ya.O. Dombrovskyi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.